LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

Search

Innoviva Inc

Cerrado

SectorSalud

20.07 0.75

Resumen

Variación precio

24h

Actual

Mínimo

19.88

Máximo

20.1

Métricas clave

By Trading Economics

Ingresos

-67M

-47M

Ventas

-3.2M

89M

P/B

Media del Sector

51.694

50.291

BPA

-0.743

Margen de beneficio

-52.559

Empleados

127

EBITDA

-63M

-27M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+175.55% upside

Dividendos

By Dow Jones

Próximas Ganancias

29 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

142M

1.3B

Apertura anterior

19.32

Cierre anterior

20.07

Noticias sobre sentimiento de mercado

By Acuity

46%

54%

127 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Innoviva Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

29 jun 2025, 23:59 UTC

Charlas de Mercado

Oil Falls Amid Abating Middle East Tensions -- Market Talk

29 jun 2025, 23:47 UTC

Charlas de Mercado

Gold Edges Lower Amid Trade Deal Hopes, Risk Appetite -- Market Talk

29 jun 2025, 23:39 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

29 jun 2025, 22:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

29 jun 2025, 22:48 UTC

Charlas de Mercado

Export Data Buoy Fisher & Paykel Healthcare Bull -- Market Talk

28 jun 2025, 08:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

28 jun 2025, 08:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 jun 2025, 20:51 UTC

Ganancias

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 jun 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 jun 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

27 jun 2025, 20:48 UTC

Charlas de Mercado

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 jun 2025, 20:46 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 jun 2025, 20:46 UTC

Charlas de Mercado

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 jun 2025, 19:31 UTC

Charlas de Mercado

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 jun 2025, 19:19 UTC

Charlas de Mercado

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 jun 2025, 19:16 UTC

Charlas de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 jun 2025, 18:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 jun 2025, 18:42 UTC

Charlas de Mercado

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 jun 2025, 18:39 UTC

Charlas de Mercado
Ganancias

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 jun 2025, 18:29 UTC

Charlas de Mercado

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 jun 2025, 18:18 UTC

Charlas de Mercado

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 jun 2025, 18:16 UTC

Charlas de Mercado

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 jun 2025, 17:16 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 jun 2025, 17:08 UTC

Ganancias

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 jun 2025, 16:52 UTC

Adquisiciones, fusiones, absorciones

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

Comparación entre iguales

Cambio de precio

Innoviva Inc Esperado

Precio Objetivo

By TipRanks

175.55% repunte

Estimación a 12 meses

Media 55 USD  175.55%

Máximo 55 USD

Mínimo 55 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

18.57 / 18.75Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

127 / 380 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.